Reductions in HbA1c with canagliflozin 100 and 300 mg versus placebo were -0.62 % ( 95 % CI -0.69 , -0.54 ; -6.8 mmol/mol [ 95 % CI -7.5 , -5.9 ] ; P < 0.001 ) and -0.73 % ( 95 % CI -0.81 , -0.65 ; -8.0 mmol/mol [ 95 % CI -8.9 , -7.1 ] ; P < 0.001 ) at 18 weeks and -0.58 % ( 95 % CI -0.68 , -0.48 ; -6.3 mmol/mol [ 95 % CI -7.4 , -5.2 ] ) and -0.73 % ( 95 % CI -0.83 , -0.63 ; -8.0 mmol/mol [ 95 % CI -9.1 , -6.9 ] ) at 52 weeks .